First head-to-head trial of colonoscopy versus faecal testing for colorectal cancer screening

Affiliations

¹ Clinical Effectiveness Research Group, University of Oslo, Oslo 0372, Norway; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway. Electronic address: michael.bretthauer@medisin.uio.no.
² Clinical Effectiveness Research Group, University of Oslo, Oslo 0372, Norway; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.

Comment

Michael Bretthauer et al. Lancet. 2025.

. 2025 Apr 12;405(10486):1204-1206.

doi: 10.1016/S0140-6736(25)00288-0. Epub 2025 Mar 27.

¹ Clinical Effectiveness Research Group, University of Oslo, Oslo 0372, Norway; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway. Electronic address: michael.bretthauer@medisin.uio.no.
² Clinical Effectiveness Research Group, University of Oslo, Oslo 0372, Norway; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.

No abstract available

Conflict of interest statement

We declare no competing interests.

Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.
Castells A, Quintero E, Bujanda L, Castán-Cameo S, Cubiella J, Díaz-Tasende J, Lanas Á, Ono A, Serra-Burriel M, Frías-Arrocha E, Hernández C, Jover R, Andreu M, Carballo F, Morillas JD, Salas D, Almazán R, Alonso-Abreu I, Banales JM, Hernández V, Portillo I, Vanaclocha-Espí M, de la Vega M; COLONPREV study investigators. Castells A, et al. Lancet. 2025 Apr 12;405(10486):1231-1239. doi: 10.1016/S0140-6736(25)00145-X. Epub 2025 Mar 27. Lancet. 2025. PMID: 40158525 Clinical Trial.